US6083903A
(en)
|
1994-10-28 |
2000-07-04 |
Leukosite, Inc. |
Boronic ester and acid compounds, synthesis and uses
|
US6838477B2
(en)
*
|
1995-04-12 |
2005-01-04 |
President And Fellows Of Harvard College |
Lactacystin analogs
|
FR2758329B1
(fr)
*
|
1997-01-16 |
1999-02-12 |
Synthelabo |
Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
|
NZ337364A
(en)
|
1997-02-15 |
2001-06-29 |
Millennium Pharm Inc |
Treatment of infarcts, ischemia and reperfusion through inhibition of NFkappaB
|
US6221888B1
(en)
*
|
1997-05-29 |
2001-04-24 |
Merck & Co., Inc. |
Sulfonamides as cell adhesion inhibitors
|
WO1999015183A1
(en)
*
|
1997-09-25 |
1999-04-01 |
Proscript Inc. |
PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-λB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES
|
ATE357509T1
(de)
*
|
1997-09-29 |
2007-04-15 |
Point Therapeutics Inc |
Stimulierung von hämatopoietischen zellen im vitro
|
US6831057B2
(en)
*
|
1997-10-28 |
2004-12-14 |
The University Of North Carolina At Chapel Hill |
Use of NF-κB inhibition in combination therapy for cancer
|
CA2219867A1
(en)
*
|
1997-10-31 |
1999-04-30 |
Jiangping Wu |
The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
|
DE19802450A1
(de)
*
|
1998-01-23 |
1999-07-29 |
Hoechst Marion Roussel De Gmbh |
Ustilipide, Verfahren zu deren Herstellung sowie deren Verwendung
|
US6075150A
(en)
|
1998-01-26 |
2000-06-13 |
Cv Therapeutics, Inc. |
α-ketoamide inhibitors of 20S proteasome
|
US6617171B2
(en)
|
1998-02-27 |
2003-09-09 |
The General Hospital Corporation |
Methods for diagnosing and treating autoimmune disease
|
FR2779653B1
(fr)
|
1998-06-11 |
2002-12-20 |
Inst Nat Sante Rech Med |
Utilisation de composes modulateurs du proteasome en therapie
|
US6838436B1
(en)
*
|
1998-07-10 |
2005-01-04 |
Osteoscreen Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6462019B1
(en)
|
1998-07-10 |
2002-10-08 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity and production for stimulating bone growth
|
US6902721B1
(en)
*
|
1998-07-10 |
2005-06-07 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6979697B1
(en)
*
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
EP0982317A1
(en)
*
|
1998-08-26 |
2000-03-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Bivalent inhibitors of the proteasome
|
KR20010080267A
(ko)
*
|
1998-10-20 |
2001-08-22 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
프로테아솜 억제제 약물 작용을 모니터링하는 방법
|
US6492333B1
(en)
|
1999-04-09 |
2002-12-10 |
Osteoscreen, Inc. |
Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
|
US6890904B1
(en)
*
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
US6649593B1
(en)
*
|
1999-10-13 |
2003-11-18 |
Tularik Inc. |
Modulators of SREBP processing
|
CA2419238A1
(en)
*
|
2000-08-16 |
2002-02-21 |
University Of Alberta |
Non-pressurized methods for the preparation of conjugated solid supports for boronic acids
|
US6919382B2
(en)
|
2000-08-31 |
2005-07-19 |
The Governors Of The University Of Alberta |
Preparation and uses of conjugated solid supports for boronic acids
|
DK1326632T3
(da)
*
|
2000-10-12 |
2007-01-15 |
Viromics Gmbh |
Protease-inhibitorer til behandling af infektioner af hepatitisvirus
|
AU2002243646B2
(en)
|
2001-01-25 |
2006-06-22 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Formulation of boronic acid compounds
|
PT1392355E
(pt)
|
2001-05-21 |
2007-03-30 |
Alcon Inc |
Utilização de inibidores do proteassoma para tratar distúrbios associados à secura ocular
|
US7112588B2
(en)
*
|
2001-05-21 |
2006-09-26 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
PT1399468E
(pt)
|
2001-05-30 |
2006-05-31 |
Novartis Ag |
Derivados do acido 2-{[n-(2-amino-3-(heteroaril ou aril)propionil)-aminoacil]-amino}-alquilboronico
|
JPWO2003033507A1
(ja)
*
|
2001-10-12 |
2005-02-03 |
杏林製薬株式会社 |
ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
|
JPWO2003033506A1
(ja)
*
|
2001-10-12 |
2005-02-03 |
杏林製薬株式会社 |
アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
|
US7524883B2
(en)
|
2002-01-08 |
2009-04-28 |
Eisai R&D Management Co., Ltd. |
Eponemycin and epoxomicin analogs and uses thereof
|
WO2003077928A1
(en)
*
|
2002-03-12 |
2003-09-25 |
Ariad Pharmaceuticals, Inc. |
Peptide analogues and uses thereof
|
ES2306858T3
(es)
*
|
2002-03-13 |
2008-11-16 |
Janssen Pharmaceutica Nv |
Derivados de carbonilamino como nuevos inhibidores de las histonadesacetilasas.
|
ATE398615T1
(de)
*
|
2002-03-13 |
2008-07-15 |
Janssen Pharmaceutica Nv |
Piperazinyl-, piperidinyl- und morpholinylderivate als neue inhibitoren von histon-deacetylase
|
OA12790A
(en)
|
2002-03-13 |
2006-07-10 |
Janssen Pharmaceutica Nv |
New inhibitors of histone deacetylase.
|
MXPA04007776A
(es)
|
2002-03-13 |
2004-10-15 |
Janssen Pharmaceutica Nv |
Derivados de sulfonilamino como nuevos inhibidores de histona deacetilasa.
|
WO2003084551A1
(de)
*
|
2002-04-05 |
2003-10-16 |
Viromics Gmbh |
Mittel zur behandlung von flaviviridae-infektionen
|
WO2003106384A2
(en)
*
|
2002-06-01 |
2003-12-24 |
Johns Hopkins University |
Novel boronic chalcone derivatives and uses thereof
|
WO2004004661A2
(en)
*
|
2002-07-09 |
2004-01-15 |
Point Therapeutics, Inc. |
Boroproline compound combination therapy
|
EP1536777B1
(en)
*
|
2002-08-14 |
2007-02-14 |
Janssen Pharmaceutica N.V. |
Use of nf-kappa b inhibitors for the treatment of mastitis
|
US20050288253A1
(en)
*
|
2002-09-09 |
2005-12-29 |
Trigen Limited |
Boronic acid salts
|
US20050119226A1
(en)
*
|
2003-09-09 |
2005-06-02 |
Trigen Limited |
Methods for synthesizing organoboronic compounds and products thereof
|
US20050176651A1
(en)
*
|
2002-09-09 |
2005-08-11 |
Trigen Limited |
Peptide boronic acids useful in making salts thereof
|
US20050282757A1
(en)
*
|
2002-09-09 |
2005-12-22 |
Trigen Limited |
Peptide boronic acid compounds useful in anticoagulation
|
JP2006509034A
(ja)
*
|
2002-09-09 |
2006-03-16 |
トライジェン・リミテッド |
選択性トロンビン阻害のための非経口製剤に有用なボロン酸塩
|
US20060084592A1
(en)
*
|
2002-09-09 |
2006-04-20 |
Trigen Limited |
Peptide boronic acid inhibitors
|
WO2004026406A1
(en)
*
|
2002-09-20 |
2004-04-01 |
Alcon, Inc. |
Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
|
CA2508348C
(en)
|
2002-12-06 |
2016-07-12 |
Millennium Pharmaceuticals, Inc. |
Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
|
CN100341880C
(zh)
*
|
2003-02-13 |
2007-10-10 |
上海仁虎制药股份有限公司 |
新型硼酸或硼酸酯类化合物、制备方法及在药学上的应用
|
WO2005007211A2
(en)
*
|
2003-07-03 |
2005-01-27 |
Medtronic Vascular Inc. |
Medical devices with proteasome inhibitors for the treatment of restenosis
|
US7576206B2
(en)
|
2003-08-14 |
2009-08-18 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7223745B2
(en)
*
|
2003-08-14 |
2007-05-29 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
MXPA06005104A
(es)
*
|
2003-11-05 |
2007-01-25 |
Palingen Inc |
Citotoxicidad de celulas b aumentada en anticuerpos de enlace a cdim.
|
US20060052390A1
(en)
*
|
2003-12-24 |
2006-03-09 |
Scios, Inc. |
Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
|
EP1729757A2
(en)
*
|
2004-02-23 |
2006-12-13 |
Trustees Of Tufts College |
Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism
|
GB0405272D0
(en)
*
|
2004-03-09 |
2004-04-21 |
Trigen Ltd |
Compounds
|
US7371875B2
(en)
*
|
2004-03-12 |
2008-05-13 |
Miikana Therapeutics, Inc. |
Cytotoxic agents and methods of use
|
SG10201600029PA
(en)
|
2004-03-30 |
2016-02-26 |
Millennium Pharm Inc |
Synthesis of boronic ester and acid compounds
|
AU2016202747B2
(en)
*
|
2004-03-30 |
2017-11-23 |
Millennium Pharmaceuticals, Inc. |
Synthesis of boronic ester and acid compounds
|
US8198270B2
(en)
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
SG152239A1
(en)
|
2004-04-15 |
2009-05-29 |
Proteolix Inc |
Compounds for proteasome enzyme inhibition
|
PT2030981E
(pt)
|
2004-05-10 |
2014-10-14 |
Onyx Therapeutics Inc |
Compostos para inibição da enzima proteassoma
|
JP2008504292A
(ja)
|
2004-06-24 |
2008-02-14 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
免疫増強用の化合物
|
ATE553077T1
(de)
|
2004-07-23 |
2012-04-15 |
Nuada Llc |
Peptidaseinhibitoren
|
WO2006010750A1
(en)
|
2004-07-28 |
2006-02-02 |
Janssen Pharmaceutica N.V. |
Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
|
US20060088471A1
(en)
|
2004-10-20 |
2006-04-27 |
Proteolix, Inc. |
Compounds for enzyme inhibition
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
CN101098889A
(zh)
|
2004-11-05 |
2008-01-02 |
盘林京有限公司 |
抗体导致的细胞膜损伤
|
US8017395B2
(en)
|
2004-12-17 |
2011-09-13 |
Lifescan, Inc. |
Seeding cells on porous supports
|
US20070098685A1
(en)
*
|
2005-01-19 |
2007-05-03 |
Brand Stephen J |
Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
|
JP5475235B2
(ja)
|
2005-01-21 |
2014-04-16 |
アステックス・セラピューティクス・リミテッド |
医薬化合物
|
CA2595749A1
(en)
*
|
2005-01-27 |
2006-08-03 |
Research Development Foundation |
Combination therapy with triterpenoid compounds and proteasome inhibitors
|
US7468383B2
(en)
*
|
2005-02-11 |
2008-12-23 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
PT3424932T
(pt)
*
|
2005-02-16 |
2021-05-19 |
Anacor Pharmaceuticals Inc |
Boronoftalidas para utilização terapêutica
|
EP1863513A2
(en)
*
|
2005-03-11 |
2007-12-12 |
The University of North Carolina at Chapel Hill |
Potent and specific immunoproteasome inhibitors
|
BRPI0609861A2
(pt)
*
|
2005-04-29 |
2010-05-11 |
Kosan Biosciences Inc |
uso de 17-aag ou 17-ag ou um pró-fármaco de ambos em combinação com um inibidor de proteassoma na preparação de formulações farmacêuticas para tratar mieloma múltiplo
|
US8138198B2
(en)
|
2005-05-18 |
2012-03-20 |
Angibaud Patrick Rene |
Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
|
AU2006202209B2
(en)
*
|
2005-05-27 |
2011-04-14 |
Lifescan, Inc. |
Amniotic fluid derived cells
|
CN101484575B
(zh)
*
|
2005-06-08 |
2013-10-02 |
森托科尔公司 |
用于眼变性的细胞疗法
|
US20090017006A1
(en)
*
|
2005-07-06 |
2009-01-15 |
Biodevelops Pharma Entwicklung Gmbh |
Use of a compound for enhancing the expression of membrane proteins on the cell surface
|
EP1752467A1
(en)
|
2005-08-10 |
2007-02-14 |
4Sc Ag |
Inhibitors of cancer cell, t-cell and keratinocyte proliferation
|
US7531517B2
(en)
|
2005-08-10 |
2009-05-12 |
4Sc Ag |
Inhibitors of cancer cell, T-cell and keratinocyte proliferation
|
US20070059382A1
(en)
*
|
2005-09-09 |
2007-03-15 |
Board Of Regents, Univ. And Comm. College System Of Nevada... |
Medical treatment of breast cancer with boric acid materials
|
CN105237621A
(zh)
|
2005-11-09 |
2016-01-13 |
欧尼斯治疗公司 |
用于酶抑制的化合物
|
EP1956908A2
(en)
*
|
2005-12-08 |
2008-08-20 |
Cytokinetics, Inc. |
Certain compositions and methods of treatment
|
RU2008131324A
(ru)
*
|
2005-12-30 |
2010-02-10 |
Анакор Фармасьютикалз, Инк. (Us) |
Борсодержащие малые молекулы
|
WO2007082874A1
(en)
|
2006-01-19 |
2007-07-26 |
Janssen Pharmaceutica N.V. |
Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
|
CN101370789B
(zh)
*
|
2006-01-19 |
2012-05-30 |
詹森药业有限公司 |
作为组蛋白脱乙酰酶抑制剂的吡啶和嘧啶衍生物
|
JP5137849B2
(ja)
*
|
2006-01-19 |
2013-02-06 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体
|
DK1981874T3
(da)
*
|
2006-01-19 |
2009-09-28 |
Janssen Pharmactuica N V |
Aminophenylderivater som nye inhibitorer af histondeacetylase
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
ES2728455T3
(es)
|
2006-02-16 |
2019-10-24 |
Anacor Pharmaceuticals Inc |
Moléculas pequeñas que contienen boro como agentes antiinflamatorios
|
AR060358A1
(es)
*
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
US8741643B2
(en)
|
2006-04-28 |
2014-06-03 |
Lifescan, Inc. |
Differentiation of pluripotent stem cells to definitive endoderm lineage
|
DE102006026464A1
(de)
|
2006-06-01 |
2007-12-06 |
Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma |
Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
|
WO2007143600A2
(en)
*
|
2006-06-05 |
2007-12-13 |
Incyte Corporation |
Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
|
EP2041158B1
(en)
|
2006-06-19 |
2013-04-17 |
Onyx Therapeutics, Inc. |
Peptide epoxyketones for proteasome inhibition
|
AU2007296259A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Janssen Pharmaceutica Nv |
Combinations of class-I specific histone deacetylase inhibitors with proteasome inhibitors
|
EA020276B1
(ru)
*
|
2006-09-15 |
2014-10-30 |
Янссен Фармацевтика Нв |
Ингибиторы гистоновых дезацетилаз с сочетанной активностью в отношении гистоновых дезацетилаз класса i и класса ii в комбинации с ингибиторами протеасом
|
EP2073803B1
(en)
|
2006-10-12 |
2018-09-19 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
US8883790B2
(en)
|
2006-10-12 |
2014-11-11 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
AU2007221966A1
(en)
*
|
2006-12-08 |
2008-06-26 |
Centenary Institute Of Cancer Medicine And Cell Biology |
Assay for response to proteasome inhibitors
|
JO3396B1
(ar)
|
2007-06-20 |
2019-10-20 |
Anacor Pharmaceuticals Inc |
جزيئات صغيرة تحتوي على البورون
|
US9080145B2
(en)
*
|
2007-07-01 |
2015-07-14 |
Lifescan Corporation |
Single pluripotent stem cell culture
|
CN101952415B
(zh)
|
2007-07-31 |
2017-06-27 |
生命扫描有限公司 |
人胚胎干细胞的分化
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
LT2170396T
(lt)
|
2007-08-03 |
2017-03-10 |
Summit (Oxford) Limited |
Vaistų deriniai, skirti diušeno raumenų distrofijos gydymui
|
AU2016253697A1
(en)
*
|
2007-08-06 |
2016-11-24 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
WO2009020448A1
(en)
*
|
2007-08-06 |
2009-02-12 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
US7442830B1
(en)
|
2007-08-06 |
2008-10-28 |
Millenium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
EA034601B1
(ru)
*
|
2007-08-06 |
2020-02-25 |
Милленниум Фармасьютикалз, Инк. |
Способ получения бороновых кислот
|
JP2010539183A
(ja)
*
|
2007-09-12 |
2010-12-16 |
ドクター・レディーズ・ラボラトリーズ・リミテッド |
ボルテゾミブおよびその生成のためのプロセス
|
US20090076031A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched bortezomib
|
CL2008002966A1
(es)
|
2007-10-04 |
2010-06-25 |
Onyx Therapeutics Inc |
Compuesto tetrapeptido ceto-epoxido cristalino; sal citrato cristalina del compuesto; metodos de preparacion; compuesto intermediario cristalino; metodo de preparacion; y uso para tratar cancer, enfermedad autoinmune, afeccion relacionada con trasplante, enfermedad neurodegenerativa, afeccion asociada con fibrosis, entre otros.
|
US7838673B2
(en)
*
|
2007-10-16 |
2010-11-23 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
US20090110688A1
(en)
*
|
2007-10-24 |
2009-04-30 |
Georg Fertig |
Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
|
CN107574142B
(zh)
|
2007-11-27 |
2021-07-06 |
生命扫描有限公司 |
人胚胎干细胞的分化
|
CN101220048B
(zh)
*
|
2007-12-14 |
2012-08-15 |
江苏先声药物研究有限公司 |
ZnCl2催化下的蒎烷二醇酯的制备方法
|
JP2011506560A
(ja)
|
2007-12-20 |
2011-03-03 |
ノバルティス アーゲー |
Pi3キナーゼ阻害剤として用いられるチアゾール誘導体
|
WO2009105570A2
(en)
|
2008-02-21 |
2009-08-27 |
Centocor Ortho Biotech Inc. |
Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
|
KR101672511B1
(ko)
|
2008-03-06 |
2016-11-03 |
아나코르 파마슈티칼스 인코포레이티드 |
소염제로써 붕소가 함유된 소분자
|
WO2009140309A2
(en)
*
|
2008-05-12 |
2009-11-19 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
MX349769B
(es)
|
2008-06-17 |
2017-08-11 |
Millennium Pharm Inc |
Compuestos de éster boronato y composiciones farmacéuticas de los mismos.
|
JP5734183B2
(ja)
|
2008-06-30 |
2015-06-17 |
ヤンセン バイオテツク,インコーポレーテツド |
多能性幹細胞の分化
|
CN101638414B
(zh)
*
|
2008-07-30 |
2014-01-08 |
江苏先声药物研究有限公司 |
肽硼酸及其酯类化合物、制备方法及其用途
|
US20100028307A1
(en)
*
|
2008-07-31 |
2010-02-04 |
O'neil John J |
Pluripotent stem cell differentiation
|
WO2010028005A1
(en)
|
2008-09-04 |
2010-03-11 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
EP2348863A4
(en)
*
|
2008-09-04 |
2012-03-07 |
Anacor Pharmaceuticals Inc |
BORN SMALL MOLECULES
|
AR075090A1
(es)
*
|
2008-09-29 |
2011-03-09 |
Millennium Pharm Inc |
Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
|
WO2010045503A1
(en)
*
|
2008-10-15 |
2010-04-22 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-protozoal agents
|
EA035100B1
(ru)
|
2008-10-21 |
2020-04-28 |
Оникс Терапьютикс, Инк. |
Комбинированная терапия с применением пептид эпоксикетонов
|
BRPI0919885A2
(pt)
|
2008-10-31 |
2015-08-11 |
Centocor Ortho Biotech Inc |
Diferenciação de células-tronco embrionárias humanas para a linhagem endócrina pancreática
|
CA2742267C
(en)
*
|
2008-10-31 |
2019-06-04 |
Centocor Ortho Biotech Inc. |
Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
|
AU2009316583B2
(en)
*
|
2008-11-20 |
2016-04-21 |
Janssen Biotech, Inc. |
Methods and compositions for cell attachment and cultivation on planar substrates
|
RU2555538C2
(ru)
|
2008-11-20 |
2015-07-10 |
Сентокор Орто Байотек Инк. |
Культура плюрипотентных стволовых клеток на микроносителях
|
CN101747354B
(zh)
*
|
2008-12-04 |
2014-08-13 |
江苏先声药物研究有限公司 |
一类β氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
|
CN102256494A
(zh)
*
|
2008-12-17 |
2011-11-23 |
阿纳科制药公司 |
(s)-3-氨甲基-7-(3-羟基-丙氧基)-3h-苯并[c][1,2]氧杂硼杂环戊-1-醇的多晶型物
|
KR20110114562A
(ko)
|
2009-01-09 |
2011-10-19 |
썬 파마 어드밴스트 리서치 컴패니 리미티드 |
보르테조밉 함유 약학적 조성물
|
EP3021120A1
(en)
|
2009-02-20 |
2016-05-18 |
Michael P. Lisanti |
Diagnosis, prognosis, therapeutics and methods for treating neoplastic deiseases comprising determining the level of caveolin-1 in a stromal cell sample
|
JP5709766B2
(ja)
|
2009-03-12 |
2015-04-30 |
ジェネンテック, インコーポレイテッド |
造血器腫瘍の治療のためのホスホイノシチド3キナーゼ阻害剤化合物と化学療法剤の併用
|
WO2010106135A1
(en)
|
2009-03-20 |
2010-09-23 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Combined use for the treatment of ovarian carcinoma
|
TWI504598B
(zh)
|
2009-03-20 |
2015-10-21 |
Onyx Therapeutics Inc |
結晶性三肽環氧酮蛋白酶抑制劑
|
WO2010111361A1
(en)
|
2009-03-24 |
2010-09-30 |
Janssen Pharmaceutica Nv |
Biomarkers for assessing peripheral neuropathy response to treatment with a proteasome inhibitor
|
WO2010114770A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
CA2756072A1
(en)
*
|
2009-03-30 |
2010-10-14 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
WO2010114768A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-epothilone conjugates, particles, compositions, and related methods of use
|
CN102458127B
(zh)
*
|
2009-05-27 |
2014-08-27 |
赛福伦公司 |
用于治疗多发性骨髓瘤的联合治疗
|
EP2270019A1
(en)
|
2009-06-19 |
2011-01-05 |
LEK Pharmaceuticals d.d. |
New synthetic route for the preparation of alpha-amino boronic esters
|
EP2280016A1
(en)
|
2009-07-27 |
2011-02-02 |
LEK Pharmaceuticals d.d. |
New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes
|
JP2012530115A
(ja)
|
2009-06-19 |
2012-11-29 |
レツク・フアーマシユーテイカルズ・デー・デー |
置換アルカ−1−インを経由するα−アミノボロン酸誘導体の調製のための新規な合成経路
|
CN101928329B
(zh)
|
2009-06-19 |
2013-07-17 |
北京大学 |
三肽硼酸(酯)类化合物、其制备方法和应用
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
DE102009027754A1
(de)
|
2009-07-15 |
2011-05-05 |
Schubert, Ulrich, Dr. |
Verfahren zur Hemmung der Reifung von dendritischen Zellen
|
GB2485113B
(en)
|
2009-07-20 |
2016-12-28 |
Janssen Biotech Inc |
Differentiation of human embryonic stem cells into cells of the pancreatic endoderm lineage
|
RU2540021C2
(ru)
*
|
2009-07-20 |
2015-01-27 |
Янссен Байотек, Инк. |
Дифференцировка эмбриональных стволовых клеток человека
|
EP2456862A4
(en)
|
2009-07-20 |
2013-02-27 |
Janssen Biotech Inc |
DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS
|
MX2012001156A
(es)
*
|
2009-07-28 |
2012-05-08 |
Anacor Pharmaceuticals Inc |
Moleculas que contienen boro trisustituidas.
|
WO2011019618A1
(en)
*
|
2009-08-14 |
2011-02-17 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
WO2011022502A1
(en)
|
2009-08-18 |
2011-02-24 |
Georgetown University |
Boronic acid compositions and methods related to cancer
|
MX2012002031A
(es)
*
|
2009-08-19 |
2012-07-04 |
Anacor Pharmaceuticals Inc |
Moleculas pequeñas que contienen boro como agentes antiprotozoarios.
|
CN102625807B
(zh)
|
2009-09-08 |
2016-03-09 |
霍夫曼-拉罗奇有限公司 |
4-取代的吡啶-3-基-甲酰胺化合物和使用方法
|
US20110124597A1
(en)
*
|
2009-09-25 |
2011-05-26 |
Anacor Pharmaceuticals, Inc. |
Boron containing small molecules
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
SI2519231T1
(sl)
|
2009-10-01 |
2017-07-31 |
Janssen Pharmaceutica Nv |
Proteasomski inhibitorji za zdravljenje raka
|
WO2011049971A1
(en)
|
2009-10-20 |
2011-04-28 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
WO2011060199A1
(en)
*
|
2009-11-11 |
2011-05-19 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
WO2011060179A1
(en)
|
2009-11-13 |
2011-05-19 |
Onyx Therapeutics, Inc |
Use of peptide epoxyketones for metastasis suppression
|
CN102725300B
(zh)
*
|
2009-12-22 |
2015-03-11 |
赛福伦公司 |
蛋白酶体抑制剂及其制备、纯化、和应用的方法
|
RU2586506C2
(ru)
|
2009-12-23 |
2016-06-10 |
Янссен Байотек, Инк. |
Дифференцировка человеческих эмбриональных стволовых клеток
|
CN102741395B
(zh)
|
2009-12-23 |
2016-03-16 |
詹森生物科技公司 |
人胚胎干细胞的分化
|
WO2011090940A1
(en)
|
2010-01-19 |
2011-07-28 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
US8716478B2
(en)
|
2010-01-27 |
2014-05-06 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
AU2011223900A1
(en)
|
2010-03-01 |
2012-09-13 |
Janssen Biotech, Inc. |
Methods for purifying cells derived from pluripotent stem cells
|
US9359398B2
(en)
*
|
2010-03-01 |
2016-06-07 |
Onyx Therapeutics, Inc. |
Compounds for immunoproteasome inhibition
|
US9061037B2
(en)
*
|
2010-03-18 |
2015-06-23 |
Innopharma, Inc. |
Stable bortezomib formulations
|
US8263578B2
(en)
|
2010-03-18 |
2012-09-11 |
Innopharma, Inc. |
Stable bortezomib formulations
|
WO2011116348A1
(en)
|
2010-03-19 |
2011-09-22 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-protozoal agent
|
EP3187585A1
(en)
|
2010-03-25 |
2017-07-05 |
Oregon Health&Science University |
Cmv glycoproteins and recombinant vectors
|
AU2013204868B2
(en)
*
|
2010-03-31 |
2016-10-13 |
Millennium Pharmaceuticals, Inc. |
Derivatives of 1-amino-2-cyclopropylethylboronic acid
|
EA029521B1
(ru)
*
|
2010-03-31 |
2018-04-30 |
Милленниум Фармасьютикалз, Инк. |
Производные 1-амино-2-циклопропилэтилбороновой кислоты
|
BR112012025264A2
(pt)
|
2010-04-07 |
2019-09-24 |
Onyx Therapeutics Inc |
inibidor de imunoproteassoma de e´poxicetona peptídica cristalina.
|
CN101812026B
(zh)
*
|
2010-04-12 |
2013-08-28 |
亚邦医药股份有限公司 |
一种硼替佐米的合成方法
|
CN102946879B
(zh)
|
2010-04-19 |
2015-04-22 |
尼基制药公司 |
一种蛋白酶体抑制剂和镓络合物在制备治疗增殖性疾病的药物中的应用
|
US8809282B2
(en)
|
2010-05-06 |
2014-08-19 |
Duke University |
Method of reducing titers of antibodies specific for a therapeutic agent
|
MX351515B
(es)
|
2010-05-12 |
2017-10-17 |
Janssen Biotech Inc |
Diferenciacion de celulas madre embrionarias humanas.
|
AU2011255647A1
(en)
|
2010-05-18 |
2012-11-15 |
Cerulean Pharma Inc. |
Compositions and methods for treatment of autoimmune and other diseases
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
CA2809305C
(en)
|
2010-08-31 |
2019-06-11 |
Janssen Biotech, Inc. |
Differentiation of pluripotent stem cells
|
US9528090B2
(en)
|
2010-08-31 |
2016-12-27 |
Janssen Biotech, Inc. |
Differentiation of human embryonic stem cells
|
AU2011296381B2
(en)
|
2010-08-31 |
2016-03-31 |
Janssen Biotech, Inc. |
Differentiation of human embryonic stem cells
|
US9126997B1
(en)
|
2010-09-07 |
2015-09-08 |
Northwestern University |
Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
|
EP2613788B1
(en)
|
2010-09-07 |
2017-06-21 |
Anacor Pharmaceuticals, Inc. |
Benzoxaborole derivatives for treating bacterial infections
|
US8962572B2
(en)
|
2010-10-05 |
2015-02-24 |
Fresenius Kabi Usa, Llc |
Bortezomib formulations
|
EP2627636B1
(en)
|
2010-10-14 |
2015-09-02 |
Synthon BV |
Process for making bortezomib and the intermediates for the process
|
US8987257B2
(en)
|
2011-01-31 |
2015-03-24 |
Novartis Ag |
Heterocyclic derivatives
|
TW201309303A
(zh)
*
|
2011-03-03 |
2013-03-01 |
Cephalon Inc |
用於治療狼瘡的蛋白酶體抑制劑
|
US9272014B2
(en)
|
2011-03-29 |
2016-03-01 |
Texas Tech University System |
Galectin-3C combination therapy for human cancer
|
US9561284B2
(en)
|
2011-03-31 |
2017-02-07 |
Nanocarrier Co., Ltd. |
Pharmaceutical composition containing a block copolymer bound to a boronic acid compound
|
PL2691530T3
(pl)
|
2011-06-10 |
2019-02-28 |
Oregon Health & Science University |
Glikoproteiny i rekombinowane wektory CMV
|
US20140121182A1
(en)
*
|
2011-06-22 |
2014-05-01 |
Cephalon, Inc. |
Proteasome inhibitors and processes for their preparation, purification and use
|
US8481655B2
(en)
|
2011-07-27 |
2013-07-09 |
Wacker Chemical Corporation |
Copper complexes of amino-functional organosilicon compounds and their use
|
JP6002222B2
(ja)
|
2011-08-11 |
2016-10-05 |
ヤンセン ファーマシューティカ エヌ.ベー. |
がん治療用予測因子
|
WO2013021032A1
(en)
|
2011-08-11 |
2013-02-14 |
Janssen Pharmaceutica Nv |
Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone
|
DK2744332T3
(en)
|
2011-08-19 |
2017-01-16 |
Glaxo Group Ltd |
BENZOFURAN COMPOUNDS FOR TREATMENT OF HEPATITIS C VIRUS INFECTIONS
|
ES2929179T3
(es)
*
|
2011-08-30 |
2022-11-25 |
Tufts College |
Inhibidores del proteasoma activados por FAP para el tratamiento de tumores sólidos
|
US20130189754A1
(en)
|
2011-09-12 |
2013-07-25 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
EP2771489B1
(en)
|
2011-10-28 |
2018-07-04 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to nae inhibitors
|
EP2771342B1
(en)
|
2011-10-28 |
2016-05-18 |
Novartis AG |
Purine derivatives and their use in the treatment of disease
|
JP6286358B2
(ja)
|
2011-11-11 |
2018-02-28 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤に応答するバイオマーカー
|
EP2776043B1
(en)
|
2011-11-11 |
2018-02-21 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to proteasome inhibitors
|
US9114177B2
(en)
|
2011-11-17 |
2015-08-25 |
The University Of Tokyo |
Block copolymer having phenylboronic acid group introduced therein, and use thereof
|
AU2012355698B2
(en)
|
2011-12-22 |
2018-11-29 |
Janssen Biotech, Inc. |
Differentiation of human embryonic stem cells into single hormonal insulin positive cells
|
WO2013110005A1
(en)
|
2012-01-18 |
2013-07-25 |
Wisconsin Alumni Research Foundation |
Boronate-mediated delivery of molecules into cells
|
US9732101B2
(en)
|
2012-01-18 |
2017-08-15 |
Wisconsin Alumni Research Foundation |
Bioreversible boronates for delivery of molecules into cells
|
EP2810066B1
(en)
|
2012-01-24 |
2019-07-31 |
Millennium Pharmaceuticals, Inc. |
Methods of treatment of cancer
|
GB2523211B
(en)
|
2012-01-27 |
2020-03-18 |
Univ Jefferson |
MCT protein inhibitor-related prognostic and therapeutic methods
|
CN104254544B
(zh)
|
2012-02-08 |
2017-04-26 |
Igm生物科学有限公司 |
Cdim结合蛋白及其用途
|
AU2013227219A1
(en)
|
2012-03-02 |
2014-10-23 |
Dr. Reddy's Laboratories Limited |
Pharmaceutical compositions comprising boronic acid compounds
|
KR20140131999A
(ko)
|
2012-03-07 |
2014-11-14 |
얀센 바이오테크 인코포레이티드 |
만능 줄기 세포의 증폭 및 유지를 위한 한정 배지
|
CA2784240C
(en)
|
2012-03-27 |
2014-07-08 |
Innopharma, Inc. |
Stable bortezomib formulations
|
US10213432B2
(en)
|
2012-05-16 |
2019-02-26 |
Novartis Ag |
Dosage regimen for a PI-3 kinase inhibitor
|
CN108103006A
(zh)
|
2012-06-08 |
2018-06-01 |
詹森生物科技公司 |
人胚胎干细胞向胰腺内分泌细胞的分化
|
ES2631608T3
(es)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Variante de la glicoproteína Env del VIH-1
|
UY34897A
(es)
|
2012-07-09 |
2014-01-31 |
Onyx Therapeutics Inc |
Profarmacos de inhibidores peptidicos de expoxi cetona proteasa
|
JP2013006855A
(ja)
*
|
2012-09-03 |
2013-01-10 |
Millennium Pharmaceuticals Inc |
プロテアソーム阻害剤
|
WO2014041324A1
(en)
*
|
2012-09-11 |
2014-03-20 |
Cipla Limited |
Process for preparing of bortezamib
|
CA2886783A1
(en)
|
2012-10-01 |
2014-04-10 |
Millennium Pharmaceuticals, Inc. |
Biomarkers and methods to predict response to inhibitors and uses thereof
|
WO2014072985A1
(en)
|
2012-11-06 |
2014-05-15 |
Natco Pharma Limited |
Novel boronic acid derivatives as anti cancer agents
|
JP2015536342A
(ja)
|
2012-11-16 |
2015-12-21 |
シルパ・メディケア・リミテッドShilpa Medicare Limited |
結晶ボルテゾミブの方法
|
WO2014097306A1
(en)
|
2012-12-21 |
2014-06-26 |
Natco Pharma Limited |
Stable and pure polymorphic form of bortezomib
|
US10370644B2
(en)
|
2012-12-31 |
2019-08-06 |
Janssen Biotech, Inc. |
Method for making human pluripotent suspension cultures and cells derived therefrom
|
KR102084561B1
(ko)
|
2012-12-31 |
2020-03-04 |
얀센 바이오테크 인코포레이티드 |
췌장 내분비 세포로의 분화를 위한 공기-액체 계면에서의 인간 배아 줄기세포의 배양
|
JP6529440B2
(ja)
|
2012-12-31 |
2019-06-12 |
ヤンセン バイオテツク,インコーポレーテツド |
膵内分泌細胞への分化のためのヒト多能性細胞の懸濁及びクラスタリング
|
KR102036780B1
(ko)
|
2012-12-31 |
2019-10-25 |
얀센 바이오테크 인코포레이티드 |
Hb9 조절제를 사용하는 인간 배아 줄기세포의 췌장 내분비 세포로의 분화
|
RU2737434C2
(ru)
|
2013-03-13 |
2020-11-30 |
Форма Терапьютикс, Инк. |
Новые соединения и композиции для ингибирования fasn
|
WO2014170628A1
(en)
|
2013-04-16 |
2014-10-23 |
Cipla Limited |
Process for the preparation of bortezomib mannitol ester
|
US10022372B2
(en)
|
2013-04-19 |
2018-07-17 |
Thomas Jefferson University |
Caveolin-1 related methods for treating glioblastoma with temozolomide
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
WO2015003146A1
(en)
|
2013-07-03 |
2015-01-08 |
Georgetown University |
Boronic acid derivatives of resveratrol for activating deacetylase enzymes
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
MX2016003979A
(es)
|
2013-10-03 |
2016-06-15 |
Millennium Pharm Inc |
Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica.
|
EP2873423B1
(en)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
CN104586776B
(zh)
*
|
2013-10-30 |
2017-05-17 |
扬子江药业集团上海海尼药业有限公司 |
以硼替佐米为活性成分的制剂及其制备方法
|
JP6468562B2
(ja)
*
|
2013-11-21 |
2019-02-13 |
国立大学法人北海道大学 |
プロテアソーム阻害性化合物
|
EP3077823B1
(en)
|
2013-12-05 |
2019-09-04 |
The Broad Institute, Inc. |
Compositions and methods for identifying and treating cachexia or pre-cachexia
|
PL3076969T3
(pl)
|
2013-12-06 |
2022-01-17 |
Novartis Ag |
Schemat dawkowania selektywnego inhibitora 3-kinazy fosfatydynozytolu alfa-izoformy
|
WO2015117136A1
(en)
|
2014-02-03 |
2015-08-06 |
Ohio State Innovation Foundation |
Boronic acid esters and pharmaceutical formulations thereof
|
EP2910557A1
(en)
*
|
2014-02-20 |
2015-08-26 |
Ikerchem, S.L. |
Enantiopure tetrasubstituted pyrrolidines as scaffolds for proteasome inhibitors and medicinal applications thereof
|
EP3141243B1
(en)
|
2014-05-08 |
2020-07-08 |
The University of Tokyo |
Pharmaceutical composition
|
CA2949056A1
(en)
|
2014-05-16 |
2015-11-19 |
Janssen Biotech, Inc. |
Use of small molecules to enhance mafa expression in pancreatic endocrine cells
|
JP2017524652A
(ja)
|
2014-05-20 |
2017-08-31 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤
|
EP3808349B1
(en)
|
2014-08-07 |
2022-10-05 |
Mayo Foundation for Medical Education and Research |
Compounds and methods for treating cancer
|
MX2017004043A
(es)
*
|
2014-10-01 |
2017-07-04 |
Merck Patent Gmbh |
Derivados de acido boronico.
|
WO2016110870A1
(en)
|
2015-01-07 |
2016-07-14 |
Emcure Pharmaceuticals Limited |
Pharmaceutical composition of bortezomid
|
MA41505A
(fr)
|
2015-02-11 |
2017-12-19 |
Millennium Pharm Inc |
Nouvelle forme cristalline d'un inhibiteur de protéasome
|
JP2018510859A
(ja)
|
2015-03-17 |
2018-04-19 |
レオン−ナノドラッグズ ゲーエムベーハー |
安定化されたボロン酸化合物を含むナノ粒子
|
EP3069730A3
(en)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
EP3072901A1
(en)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
WO2016184793A1
(en)
|
2015-05-15 |
2016-11-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
|
US10144761B2
(en)
|
2015-06-19 |
2018-12-04 |
Hanlin Scientific Inc. |
Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
|
EP3120837A1
(de)
|
2015-07-22 |
2017-01-25 |
Stada Arzneimittel Ag |
Verfahren zur herstellung einer bortezomibester-lösung
|
CN106478700B
(zh)
*
|
2015-08-26 |
2020-12-29 |
杭州雷索药业有限公司 |
硼基取代的苯胺类蛋白激酶抑制剂
|
CN106588965A
(zh)
|
2015-10-15 |
2017-04-26 |
北京大学 |
脲拟肽硼酸化合物及其药物组合物、制备方法和用途
|
CA3002954A1
(en)
|
2015-11-02 |
2017-05-11 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
EP3389715A4
(en)
|
2015-12-14 |
2019-06-12 |
David K. Thomas |
COMPOSITIONS AND METHODS FOR TREATING CARDIAL DYSFUNCTION
|
CN107151255A
(zh)
*
|
2016-03-06 |
2017-09-12 |
复旦大学 |
硼酸类化合物及其制备方法和用途
|
CN107151254A
(zh)
*
|
2016-03-06 |
2017-09-12 |
复旦大学 |
一种作为20s蛋白酶体抑制剂的硼酸类化合物及其制备方法
|
MA45479A
(fr)
|
2016-04-14 |
2019-02-20 |
Janssen Biotech Inc |
Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
|
US11447506B2
(en)
|
2016-05-09 |
2022-09-20 |
Anacor Pharmaceuticals, Inc. |
Crystal forms of crisaborole in free form and preparation method and use thereof
|
CN106008572B
(zh)
*
|
2016-05-23 |
2018-08-17 |
成都千禧莱医药科技有限公司 |
一类二肽硼酸化合物及制备方法和用途
|
AU2017282651B2
(en)
|
2016-06-21 |
2021-08-12 |
Orion Ophthalmology LLC |
Heterocyclic prolinamide derivatives
|
EP3472151A4
(en)
|
2016-06-21 |
2020-03-04 |
Orion Ophthalmology LLC |
CARBOCYCLIC PROLINAMIDE DERIVATIVES
|
JP6681284B2
(ja)
*
|
2016-06-23 |
2020-04-15 |
信越化学工業株式会社 |
糖アルコール化合物の金属低減方法
|
JP6223508B2
(ja)
*
|
2016-06-27 |
2017-11-01 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤
|
WO2018038687A1
(en)
|
2016-08-22 |
2018-03-01 |
Mustafa Nevzat Ilaç Sanayii A.Ş. |
Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
WO2018073790A1
(en)
|
2016-10-20 |
2018-04-26 |
Pfizer Inc. |
Therapeutic particles with peptide boronic acid or boronate ester compounds and methods of making and using same
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
ES2914123T3
(es)
|
2017-01-09 |
2022-06-07 |
Shuttle Pharmaceuticals Inc |
Inhibidores selectivos de la histona desacetilasa para el tratamiento de una enfermedad humana
|
CN110312727A
(zh)
|
2017-02-17 |
2019-10-08 |
费森尤斯卡比肿瘤学有限公司 |
一种改进的制备硼酸酯的方法
|
WO2018160717A1
(en)
|
2017-02-28 |
2018-09-07 |
Mayo Foundation For Medical Education And Research |
Compounds and methods for treating cancer
|
JP7289828B2
(ja)
|
2017-08-23 |
2023-06-12 |
ケザール ライフ サイエンシズ |
自己免疫疾患の治療における免疫プロテアソーム阻害剤および免疫抑制剤
|
BR112020005079A2
(pt)
|
2017-09-14 |
2020-09-15 |
Glaxosmithkline Intellectual Property Development Limited |
tratamento de combinação para câncer
|
JP2018024694A
(ja)
*
|
2017-10-03 |
2018-02-15 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤
|
NZ764393A
(en)
|
2017-11-16 |
2023-11-24 |
Principia Biopharma Inc |
Immunoproteasome inhibitors
|
WO2019099576A1
(en)
*
|
2017-11-16 |
2019-05-23 |
Principia Biopharma Inc. |
Immunoproteasome inhibitors
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
WO2019139921A1
(en)
|
2018-01-09 |
2019-07-18 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
JP2021512165A
(ja)
|
2018-01-29 |
2021-05-13 |
コグノス・セラピューティクス・インコーポレイテッド |
ボルテゾミブの腫瘍内送達
|
TW202003553A
(zh)
|
2018-03-15 |
2020-01-16 |
美商艾伯維有限公司 |
用於治療癌症之abbv-621與抗癌劑之組合
|
US11243207B2
(en)
|
2018-03-29 |
2022-02-08 |
Mayo Foundation For Medical Education And Research |
Assessing and treating cancer
|
US10793554B2
(en)
|
2018-10-29 |
2020-10-06 |
Forma Therapeutics, Inc. |
Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
|
CN109824756B
(zh)
*
|
2019-03-19 |
2022-03-22 |
山东大学 |
含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用
|
CN114437119A
(zh)
*
|
2020-10-30 |
2022-05-06 |
苏州开拓药业股份有限公司 |
一种c-Myc蛋白抑制剂及其制备方法和用途
|
US20240016815A1
(en)
*
|
2020-12-02 |
2024-01-18 |
Hoffman Technologies Llc |
Compositions and methods for modulating cancer in non-human mammals
|
TW202237143A
(zh)
*
|
2020-12-10 |
2022-10-01 |
南韓商Lg化學股份有限公司 |
酸(Boronic Acid)化合物
|
US11964993B2
(en)
|
2021-07-03 |
2024-04-23 |
Shilpa Pharma Lifesciences Limited |
Crystalline bortezomib process
|
EP4134083A1
(en)
|
2021-08-12 |
2023-02-15 |
Extrovis AG |
Pharmaceutical compositions of bortezomib
|
CN113957441B
(zh)
*
|
2021-10-29 |
2024-01-02 |
光华科学技术研究院(广东)有限公司 |
蚀刻液及其制备方法和应用
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|